Jazz Pharmaceuticals plc
General ticker "JAZZ" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.5B (TTM average)
Jazz Pharmaceuticals plc follows the US Stock Market performance with the rate: 47.1%.
Estimated limits based on current volatility of 2.4%: low 163.71$, high 171.70$
Factors to consider:
- Total employees count: 2800 as of 2024
- US accounted for 90.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Commercialization of zepzelca, Clinical trial delays, Regulatory and compliance, Market competition, Acquisition/divestiture risks
- Current price 16.3% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [88.57$, 148.78$]
- 2025-12-31 to 2026-12-31 estimated range: [85.70$, 145.70$]
Financial Metrics affecting the JAZZ estimates:
- Negative: with PPE of 5.8 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 17.61
- Positive: Operating cash flow per share per price, % of 18.27 > 12.91
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 4.47
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -6.65 <= -4.41
- Positive: 19.35 < Shareholder equity ratio, % of 34.08 <= 42.53
Short-term JAZZ quotes
Long-term JAZZ plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3,659.37MM | $3,834.20MM | $4,068.95MM |
| Operating Expenses | $3,724.90MM | $3,255.62MM | $3,352.32MM |
| Operating Income | $-65.53MM | $578.58MM | $716.63MM |
| Non-Operating Income | $-307.26MM | $-280.65MM | $-246.28MM |
| Interest Expense | $288.24MM | $289.44MM | $238.10MM |
| R&D Expense | $590.45MM | $849.66MM | $884.00MM |
| Income(Loss) | $-372.78MM | $297.93MM | $470.35MM |
| Taxes | $-158.65MM | $-119.91MM | $-91.43MM |
| Other Income(Loss) | $-9.92MM | $-3.01MM | $-1.66MM |
| Profit(Loss)* | $-224.06MM | $414.83MM | $560.12MM |
| Stockholders Equity | $3,085.73MM | $3,737.00MM | $4,093.76MM |
| Inventory | $714.06MM | $597.04MM | $480.44MM |
| Assets | $10,835.25MM | $11,393.36MM | $12,012.26MM |
| Operating Cash Flow | $1,271.98MM | $1,092.01MM | $1,395.91MM |
| Capital expenditure | $498.19MM | $23.96MM | $48.07MM |
| Investing Cash Flow | $-446.23MM | $-163.06MM | $-508.19MM |
| Financing Cash Flow | $-529.49MM | $-305.25MM | $20.52MM |
| Earnings Per Share** | $-3.58 | $6.55 | $9.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.